FOLH1 and prostate carcinoma: Despite achieving notable therapeutic effects such as prostate cancer metastases treatment with 225Ac-PSMA-617 (prostate specific membrane antigen) radiobioconjugate [3], this method cannot be used more widely due to the low availability of α-emitters.